Antiviral activities of type I interferons to SARS-CoV-2 infection

Antiviral Research

Volumn 179, Issue , 2020, Pages

  Mantlo, Emily ^a   Bukreyeva, Natalya ^a   Maruyama, Junki ^a   Paessler, Slobodan ^a,b   Huang, Cheng ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Antiviral therapy; COVID 19; Innate immune; Interferon; SARS CoV 2

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; INTERFERON; RECOMBINANT PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CYTOPATHOGENIC EFFECT; DRUG POTENCY; EC50; INTERNATIONAL STANDARD UNIT; LIMIT OF DETECTION; NONHUMAN; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VERO CELL LINE; VESICULOVIRUS; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BETACORONAVIRUS; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTION; DRUG EFFECT; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; PANDEMIC; SEVERE ACUTE RESPIRATORY SYNDROME; VIROLOGY; VIRUS PNEUMONIA;

ANIMALS; ANTIVIRAL AGENTS; BETACORONAVIRUS; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTIONS; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; PANDEMICS; PNEUMONIA, VIRAL; RECOMBINANT PROTEINS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELLS; VIRAL LOAD; VIRUS REPLICATION;

EID: 85084121805     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2020.104811     Document Type: Article

References (30)

1. Chan, J.F., Kok, K.H., Zhu, Z., Chu, H., To, K.K., Yuan, S., Yuen, K.Y., Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microb. Infect. 9 (2020), 221–236.
2. Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., Doerr, H.W., Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 361 (2003), 2045–2046.
3. Dahl, H., Linde, A., Strannegard, O., In vitro inhibition of SARS virus replication by human interferons. Scand. J. Infect. Dis. 36 (2004), 829–831.
4. Desmyter, J., Melnick, J.L., Rawls, W.E., Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol. 2 (1968), 955–961.
5. Devaraj, S.G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C.J., Tseng, C.T., Baker, S.C., Li, K., Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J. Biol. Chem. 282 (2007), 32208–32221.
6. Freundt, E.C., Yu, L., Park, E., Lenardo, M.J., Xu, X.N., Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J. Virol. 83 (2009), 6631–6640.
7. Frieman, M., Ratia, K., Johnston, R.E., Mesecar, A.D., Baric, R.S., Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 83 (2009), 6689–6705.
8. Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P., Baric, R.S., Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/golgi membrane. J. Virol. 81 (2007), 9812–9824.
9. Honda, K., Takaoka, A., Taniguchi, T., Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25 (2006), 349–360.
10. Huang, Cheng, et al. Junin virus infection Activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl Trop Dis, 6(5), 2012, e1659, 10.1371/journal.pntd.0001659.
11. Huang, C., Lokugamage, K.G., Rozovics, J.M., Narayanan, K., Semler, B.L., Makino, S., SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage. PLoS Pathog., 7, 2011.
12. Kamitani, W., Huang, C., Narayanan, K., Lokugamage, K.G., Makino, S., A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nat. Struct. Mol. Biol., 16, 2009 1134-U1132.
13. Kamitani, W., Narayanan, K., Huang, C., Lokugamage, K., Ikegami, T., Ito, N., Kubo, H., Makino, S., Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 12885–12890.
14. Kash, J.C., Muhlberger, E., Carter, V., Grosch, M., Perwitasari, O., Proll, S.C., Thomas, M.J., Weber, F., Klenk, H.D., Katze, M.G., Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80 (2006), 3009–3020.
15. Kopecky-Bromberg, S.A., Martinez-Sobrido, L., Frieman, M., Baric, R.A., Palese, P., Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81 (2007), 548–557.
16. Lu, X., Pan, J.a., Tao, J., Guo, D., SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism. Virus Gene. 42 (2011), 37–45.
17. Moriguchi, H., Sato, C., Treatment of SARS with human interferons. Lancet, 362, 2003, 1159.
18. Narayanan, K., Huang, C., Lokugamage, K., Kamitani, W., Ikegami, T., Tseng, C.T., Makino, S., Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 82 (2008), 4471–4479.
19. Narayanan, K., Huang, C., Makino, S., SARS coronavirus accessory proteins. Virus Res. 133 (2008), 113–121.
20. Narayananj, K., Huang, C., Lokugamage, K., Kamitani, W., Ikegami, T., Tseng, C.-T.K., Makino, S., Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J. Virol. 82 (2008), 4471–4479.
21. Pestka, S., Krause, C.D., Walter, M.R., Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202 (2004), 8–32.
22. Sallard, E., Lescure, F.X., Yazdanpanah, Y., Mentre, F., Peiffer-Smadja, N., Type 1 interferons as a potential treatment against COVID-19. Antivir. Res., 178, 2020, 104791.
23. Schoggins, J.W., Rice, C.M., Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1 (2011), 519–525.
24. Schoggins, J.W., Wilson, S.J., Panis, M., Murphy, M.Y., Jones, C.T., Bieniasz, P., Rice, C.M., A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 (2011), 481–485.
25. Siu, K.L., Kok, K.H., Ng, M.H., Poon, V.K., Yuen, K.Y., Zheng, B.J., Jin, D.Y., Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J. Biol. Chem. 284 (2009), 16202–16209.
26. Strayer, D.R., Dickey, R., Carter, W.A., Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Infect. Disord. - Drug Targets 14 (2014), 37–43.
27. Sun, L., Xing, Y., Chen, X., Zheng, Y., Yang, Y., Nichols, D.B., Clementz, M.A., Banach, B.S., Li, K., Baker, S.C., Chen, Z., Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PloS One, 7, 2012, e30802.
28. Varshney, B., Lal, S.K., SARS-CoV accessory protein 3b induces AP-1 transcriptional activity through activation of JNK and ERK pathways. Biochemistry 50 (2011), 5419–5425.
29. Wong, H.H., Fung, T.S., Fang, S., Huang, M., Le, M.T., Liu, D.X., Accessory proteins 8b and 8ab of severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. Virology 515 (2018), 165–175.
30. Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J. Am. Med. Assoc. 323:26 (2020), 1239–1242, 10.1001/jama.2020.2648.